Population Pharmacokinetics of Cladribine in Patients with Multiple Sclerosis

被引：0
|
作者：
Radojka M. Savic
Ana M. Novakovic
Marianne Ekblom
Alain Munafo
Mats O. Karlsson
机构：
[1] University of California San Francisco,Department of Bioengineering and Therapeutic Sciences
[2] Uppsala University,Department of Pharmaceutical Biosciences
[3] Persson Ekblom Sarl,undefined
[4] Merck Institute for Pharmacometrics,undefined
来源：
Clinical Pharmacokinetics | 2017年 / 56卷
关键词：
Multiple Sclerosis; Cladribine; Visual Predictive Check; Oral Tablet; Absorption Delay;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1245 / 1253
页数：8
相关论文
共 50 条
  • [31] Impact of Oral Cladribine on Paramagnetic Rim Lesions in Patients with Multiple Sclerosis
    Marrodan, Mariano
    Yanez, Paulina
    Calandri, Ismael
    Zarate, Maria
    Piedrabuena, Maria
    Fiol, Marcela
    Ysrraelit, Maria
    Correale, Jorge
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 921 - 921
  • [32] Experience with Cladribine in Multiple Sclerosis Patients in the Third and Fourth Year of Treatment
    Meca-Lallana, V.
    Aguirre, C.
    Diaz Perez, C.
    del Rio, B.
    Vivancos, J.
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 196 - 196
  • [33] Clinical experience with cladribine in patients with relapsing-remitting multiple sclerosis
    Hodgkinson, S.
    Lizak, N.
    Butler, E.
    Lechner-Scott, J.
    Slee, M.
    McCombe, P.
    Shaw, C.
    Skibina, O.
    Vucic, S.
    Shuey, N.
    Barnett, M.
    Parratt, J.
    Butzkueven, H.
    Jack, D.
    Fabris, J.
    Kalincik, T.
    Jokubaitis, V. G.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (09) : NP64 - NP65
  • [34] Updated safety analysis of cladribine tablets in the treatment of patients with multiple sclerosis
    Cook, S.
    Giovannoni, G.
    Leist, T.
    Syed, S.
    Nolting, A.
    Schick, R.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 465 - 466
  • [35] Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis
    Cook, Stuart
    Leist, Thomas
    Comi, Giancarlo
    Montalban, Xavier
    Giovannoni, Gavin
    Nolting, Axel
    Hicking, Christine
    Galazka, Andrew
    Sylvester, Elke
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2019, 29 : 157 - 167
  • [36] Cladribine personalised dosing to treat multiple sclerosis: observations in 208 patients
    Allen-Philbey, K.
    De Trane, S.
    Stennett, A.
    Yildiz, O.
    Adams, A.
    Turner, B.
    Marta, M.
    Gnanapavan, S.
    Bianchi, L.
    Mathews, J.
    Altmann, D.
    Giovannoni, G.
    Baker, D.
    Schmierer, K.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 522 - 523
  • [37] Updated safety analysis of cladribine tablets in the treatment of patients with multiple sclerosis
    Cook, Stuart
    Giovannoni, Gavin
    Leist, Thomas
    Syed, Sana
    Nolting, Axel
    Damian, Doris
    Schick, Regina
    NEUROLOGY, 2019, 92 (15)
  • [38] No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine
    Pakpoor, Julia
    Disanto, Giulio
    Altmann, Daniel R.
    Pavitt, Sue
    Turner, Benjamin P.
    Marta, Monica
    Juliusson, Gunnar
    Baker, David
    Chataway, Jeremy
    Schmierer, Klaus
    NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2015, 2 (06):
  • [39] Long-term experience with cladribine tablets in multiple sclerosis patients
    Oreja-Guevara, Celia
    Gomez Estevez, Irene
    Garcia Vasco, Lorena
    Quezada Sanchez, Johnny
    Diaz, Judit
    Gil-Perotin, Sara Garcia
    Alba Suarez, Elda Maria
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 966 - 966
  • [40] Severe skin reactions associated with Cladribine treatment in patients with multiple sclerosis
    Mateo-Casas, Maria
    Reyes, Saul
    De Trane, Stefania
    Yildiz, Ozlem
    Turner, Benjamin
    Mathews, Joela
    Giovannoni, Gavin
    O'toole, Edel
    Schmierer, Klaus
    NEUROLOGY, 2019, 92 (15)
12345